Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Abstract Background A prospective, randomised phase II study demonstrated clinical benefit of axitinib dose titration in a subset of treatment-naïve patients treated with axitinib for metastatic renal cell carcinoma. This analysis evaluated patient baseline characteristics that may impact overall su...

Full description

Bibliographic Details
Main Authors: Yoshihiko Tomita, Hirotsugu Uemura, Mototsugu Oya, Nobuo Shinohara, Tomonori Habuchi, Yosuke Fujii, Yoichi Kamei, Yoshiko Umeyama, Angel H. Bair, Brian I. Rini
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Cancer
Subjects:
Axitinib
Benefit with dose titration
First-line
Metastatic renal cell carcinoma
Predictive factors
Survival benefit
Online Access:http://link.springer.com/article/10.1186/s12885-018-5224-6

Internet

http://link.springer.com/article/10.1186/s12885-018-5224-6

Similar Items